Massachusetts General Hospital Cancer Center

https://www.massgeneral.org/cancer-center

 

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Suggest Clinically Meaningful Improvement in CNS DFS With Osimertinib? Does Heavily Pretreated KRAS G12C-Mutant NSCLC Respond to Sotorasib?

177 views
November 25, 2020
Comments 0
Login to view comments. Click here to Login